1,44 Data Sources : We searched PubMed using the following terms: type 2 diabetes treatment, prediabetes treatment, hypoglycemic agents, nutrition and diabetes, diabetes and cardiovascular disease
Subtle changes may appear around weeks 3 to 4
Critically, apoptosis was significantly induced in MC38 cells, as confirmed via Annexin V/PI flow cytometry and TUNEL assays, with the effects being independent of extracellular glucose levels (2 mM vs
We provide comprehensive education about the trial, ongoing support throughout the study, and fair compensation for their time and effort
Finally, implementation science will require thoughtful trial design and outcome selection
TLDR: "Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to obesity." Key findings: After stopping liraglutide, patients regained ~2.2 kg After stopping semaglutide/tirzepatide, patients regained ~9.7 kg Weight regain was proportional to initial weight loss Lifestyle changes alone DID NOT prevent regain Implication: GLP-1 receptor agonists are not a short-term solution